Literature DB >> 17637761

Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.

A Lloyd1, D Penson, S Dewilde, L Kleinman.   

Abstract

Treatment choices for metastatic prostate cancer are complex and can involve men balancing survival versus quality of life. The present study aims to elicit patient preferences with respect to the attributes of treatments for metastatic prostate cancer through a discrete choice experiment (DCE) questionnaire. Men with recently diagnosed localized prostate cancer were asked to envisage that they had metastatic disease when completing a survey. As expected, men with prostate cancer placed considerable importance on gains in survival; however, avoiding side effects of treatment was also clearly important. Survival gains should be considered alongside side effects when discussing treatment options in metastatic disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17637761     DOI: 10.1038/sj.pcan.4500992

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  8 in total

Review 1.  Risk as an attribute in discrete choice experiments: a systematic review of the literature.

Authors:  Mark Harrison; Dan Rigby; Caroline Vass; Terry Flynn; Jordan Louviere; Katherine Payne
Journal:  Patient       Date:  2014       Impact factor: 3.883

Review 2.  Patient Preference Studies for Advanced Prostate Cancer Treatment Along the Medical Product Life Cycle: Systematic Literature Review.

Authors:  Dominik Menges; Michela C Piatti; Thomas Cerny; Milo A Puhan
Journal:  Patient Prefer Adherence       Date:  2022-06-28       Impact factor: 2.314

3.  A Systematic Review of Discrete Choice Experiments in Oncology Treatments.

Authors:  Hannah Collacott; Vikas Soekhai; Caitlin Thomas; Anne Brooks; Ella Brookes; Rachel Lo; Sarah Mulnick; Sebastian Heidenreich
Journal:  Patient       Date:  2021-05-05       Impact factor: 3.883

4.  Physician preferences for non-metastatic castration-resistant prostate cancer treatment.

Authors:  Sandy Srinivas; Ateesha F Mohamed; Sreevalsa Appukkuttan; Marc Botteman; Xinyi Ng; Namita Joshi; Erica Horodniceanu; A Reginald Waldeck; Stacey J Simmons
Journal:  BMC Urol       Date:  2020-06-22       Impact factor: 2.264

5.  Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment.

Authors:  Sandy Srinivas; Ateesha F Mohamed; Sreevalsa Appukkuttan; Marc Botteman; Xinyi Ng; Namita Joshi; Jui-Hua Tsai; Jarjieh Fang; A Reginald Waldeck; Stacey J Simmons
Journal:  Cancer Med       Date:  2020-07-29       Impact factor: 4.452

6.  Evaluation of patient preference and willingness to pay for attributes of maintenance medication for chronic obstructive pulmonary disease (COPD).

Authors:  Ariane K Kawata; Leah Kleinman; Gale Harding; Sulabha Ramachandran
Journal:  Patient       Date:  2014       Impact factor: 3.883

7.  Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan.

Authors:  Masahiko Nakayama; Hisanori Kobayashi; Masateru Okazaki; Keiichiro Imanaka; Kazutake Yoshizawa; Jörg Mahlich
Journal:  Am J Mens Health       Date:  2018-05-18

8.  Physicochemical Profile of Antiandrogen Drug Bicalutamide: Solubility, Distribution, Permeability.

Authors:  Tatyana V Volkova; Olga R Simonova; German L Perlovich
Journal:  Pharmaceutics       Date:  2022-03-18       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.